Prevent Cardiac Surgery Associated AKI Trial
Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)
George Washington University
242 participants
Jul 18, 2024
INTERVENTIONAL
Conditions
Summary
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Eligibility
Inclusion Criteria3
- Adult 18-70 years of age
- Undergoing elective CPB (Cardiopulmonary Bypass) surgery
- Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min
Exclusion Criteria7
- GFR (Glomerular Filtration Rate) \<45 ml/min
- Solitary kidney
- Status post-kidney transplant
- Pregnant women
- Allergy to CoQ10
- Allergy to Glutathione
- Allergy to Cellulose
Interventions
This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06620523